Your browser doesn't support javascript.
loading
Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
Yaman, Samet; Bilgin, Burak; Sendur, Mehmet An; Hizal, Mutlu; Akinci, Muhammed Bülent; Yalçin, Bulent.
Affiliation
  • Yaman S; Department of Internal Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey.
  • Bilgin B; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, Turkey.
  • Sendur MA; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, Turkey.
  • Hizal M; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, Turkey.
  • Akinci MB; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, Turkey.
  • Yalçin B; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, Turkey.
Future Oncol ; 15(9): 925-927, 2019 Mar.
Article in En | MEDLINE | ID: mdl-30854890
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Protein Kinase Inhibitors / Kidney Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: Future Oncol Year: 2019 Document type: Article Affiliation country: Turkey Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Protein Kinase Inhibitors / Kidney Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: Future Oncol Year: 2019 Document type: Article Affiliation country: Turkey Country of publication: United kingdom